AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer’s Disease
August 01, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, Aug. 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
July 17, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase...
AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome
July 11, 2019 08:00 ET
|
AC Immune SA
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndromePresentations underscore significant need and opportunity for studying Alzheimer’s...
AC Immune Announces Election of New Chairman of the Board at Annual General Meeting
June 28, 2019 08:36 ET
|
AC Immune SA
LAUSANNE, Switzerland, June 28, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer’s in Down Syndrome
June 27, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, June 27, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering precision...
AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease
June 20, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, June 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune Reports Q1 2019 Financial Results and Business Update
May 15, 2019 07:00 ET
|
AC Immune SA
Lausanne, Switzerland, May 15, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in...
AC Immune Reports Q1 2019 Financial Results and Business Update
May 15, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, May 15, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision...
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
April 01, 2019 07:00 ET
|
AC Immune SA
Lausanne, Switzerland, April 1, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
April 01, 2019 07:00 ET
|
AC Immune SA
LAUSANNE, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...